Related Experiment Video

Updated: Aug 9, 2025

Author Spotlight: Unraveling Vitamin A Transport Mechanisms — Linking Liver Receptors to Vision Health Through RBPR2 and RBP4 Interactions
08:18

Author Spotlight: Unraveling Vitamin A Transport Mechanisms — Linking Liver Receptors to Vision Health Through RBPR2 and RBP4 Interactions

Published on: October 4, 2024

1.2K

Novel Therapeutic Potential of Retinoid-Related Orphan Receptor α in Cardiovascular Diseases

Yun Chen1, Shu-Ping Zhang1, Wei-Wei Gong1

  • 1Department of Pharmacology, School of Pharmacy, Nantong University, Nantong 226001, China.

International Journal of Molecular Sciences
|February 25, 2023
PubMed

Insights

Retinoid-related orphan receptor alpha (RORα) plays a protective role in cardiovascular diseases by regulating inflammation, apoptosis, and oxidative stress. Further research and multidisciplinary approaches are needed to translate RORα-based therapies from the lab to clinical practice.

Area of Science:

  • Endocrinology
  • Cardiovascular Biology
  • Pharmacology

Background:

  • Retinoid-related orphan receptor alpha (RORα) is a nuclear hormone receptor subfamily.
  • RORα influences numerous physiological and pathological cardiovascular processes.

Purpose of the Study:

  • To review the role of RORα in the cardiovascular system.
  • To analyze advances, limitations, and strategies for RORα-related cardiovascular drugs.

Main Methods:

  • Literature review of RORα's function in cardiovascular diseases.
  • Analysis of RORα's regulatory mechanisms (inflammation, apoptosis, autophagy, oxidative stress, ER stress, mitochondrial function).
  • Examination of synthetic RORα agonists and antagonists.

Main Results:

  • RORα exhibits protective roles against atherosclerosis, ischemia, diabetic cardiomyopathy, hypertension, and hypertrophy.
  • RORα modulates key cellular pathways involved in cardiovascular pathology.
  • Development of synthetic RORα modulators offers therapeutic potential.

Conclusions:

  • RORα is a promising therapeutic target for cardiovascular diseases.
  • Challenges remain in translating RORα research into clinical applications.
  • Multidisciplinary research is crucial for advancing RORα-based cardiovascular therapies.
Keywords:
agonistcardiovascular diseasesligandretinoid-related orphan receptor αstaggerer mutant mice

More Related Videos

Author Spotlight: Investigating Physiological Functions of Vitamin A Transporters Using HPLC-Based Vitamin A Profiling05:03

Author Spotlight: Investigating Physiological Functions of Vitamin A Transporters Using HPLC-Based Vitamin A Profiling

Published on: December 27, 2024

1.2K
Assessment of Vascular Regeneration in the CNS Using the Mouse Retina07:32

Assessment of Vascular Regeneration in the CNS Using the Mouse Retina

Published on: June 23, 2014

14.5K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
224
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
213
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
3.0K
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.4K
Regulation of the Cardiovascular System01:27

Regulation of the Cardiovascular System

The regulation of the cardiovascular system allows the body to adapt to various demands and maintain homeostasis.
The regulation of the cardiovascular system involves the autonomic nervous system (ANS), baroreceptors, and chemoreceptors, ensuring that heart rate and blood pressure are appropriately modulated in response to varying physiological demands.
The ANS comprises two main divisions: the sympathetic and parasympathetic nervous systems. The sympathetic nervous system enhances...
1.3K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
479